Abstract

The incentivization and remuneration of clinical trial participants is a central topic in medical ethics. The possibility to shorten the Covid-pandemic through controlled human infection studies lends the topic renewed relevance. We summarize evidence from economics to demonstrate that many of the central questions surrounding human subject payment can be answered empirically.

Materials

Machine-Readable Metadata

This page includes Schema.org ScholarlyArticle JSON-LD and alternate links in the HTML head for Markdown, LaTeX source bundles, Word-source text, and plain text when available.